menu
    • menu
    [{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell Therapy","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"PrimeVigilance Ltd | Data Investigation Company Europe","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NVDX3","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"PrimeVigilance Ltd | Data Investigation Company Europe","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NVDX3","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Safety Trial with NVDX3

                            Details : NVDX3 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wrist Fractures.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Proof-of-concept Study with NVDX3 for Treatment of Distal Radius Fractures.

                            Details : NVDX3 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wrist Fractures.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 14, 2023

                            Lead Product(s) : NVDX3

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoe...

                            Details : NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility​ in patients with CPT.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 17, 2023

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Novadip Biosciences

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone N...

                            Details : NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : NVD-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bone Therapeutics

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Bone Therapeutics

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Osteoblastic Cell,Allogeneic Bone-Forming Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bone Therapeutics Publishes Results of ALLOB Phase I/IIa Study for the Treatment of Delayed-Union Fractures in...

                            Details : The Phase I/IIa study was a six-month open-label trial. It evaluated the safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.

                            Product Name : ALLOB

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 30, 2021

                            Lead Product(s) : Allogeneic Osteoblastic Cell,Allogeneic Bone-Forming Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bone Therapeutics

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Bone Therapeutics

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Bone-Forming Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures

                            Details : Allogeneic Bone-Forming Cell Therapy is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Fractures, Ununited.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 25, 2013

                            Lead Product(s) : Allogeneic Bone-Forming Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth